Robert W Duggan, 10% Owner, Director, Co-Chief Executive Officer, on June 12, 2026, executed a purchase for 3,810,000 shares in Summit Therapeutics (SMMT) for $49,987,200. Following the Form 4 filing with the SEC, Duggan has control over a total of 610,015,809 common shares of the company, with 573,883,879 shares held directly and 36,131,930 controlled indirectly.
SEC Filing:
Price: $13.62, Change: $+0.54, Percent Change: +4.09%
J Danforth Quayle, Director, on June 10, 2026, sold 14,525 shares in Carvana (CVNA) for $1,016,750. Following the Form 4 filing with the SEC, Quayle has control over a total of 277,460 Class A common shares of the company, with 214,960 shares held directly and 62,500 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1690820/000121041226000006/xslF345X05/wk-form4_1781213824.xml
Anthony Grillo, Director, on June 11, 2026, sold 3,000 shares in Littelfuse (LFUS) for $1,355,867. Following the Form 4 filing with the SEC, Grillo has control over a total of 64,928 common shares of the company, with 64,928 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/889331/000107084726000010/xslF345X05/wk-form4_1781213474.xml
D James Bidzos, Director, Executive Chairman, President, & CEO, on June 09, 2026, sold 3,300 shares in Verisign (VRSN) for $938,169. Following the Form 4 filing with the SEC, Bidzos has control over a total of 436,039 common shares of the company, with 436,039 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1014473/000120481626000014/xslF345X05/wk-form4_1781213570.xml